Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRLM.L Regulatory News (RLM)

  • There is currently no data for RLM

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

12 Oct 2017 10:58

RNS Number : 4478T
Realm Therapeutics PLC
12 October 2017
 

TR-1: Standard form for notification of major holdings

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i

1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:

REALM THERAPEUTICS PLC

1b. Please indicate if the issuer is a non-UK issuer (please mark with an "X" if appropriate)

Non-UK issuer

2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments

An event changing the breakdown of voting rights

Other (please specify)iii: Placing of 66,396,485 shares

X

3. Details of person subject to the notification obligationiv

Name

SUSSEX TRADING COMPANY LTD

City and country of registered office (if applicable)

LONDON, UK.

4. Full name of shareholder(s) (if different from 3.)v

Name

City and country of registered office (if applicable)

5. Date on which the threshold was crossed or reachedvi:

10TH OCTOBER 2017

6. Date on which issuer notified (DD/MM/YYYY):

10TH OCTOBER 2017

7. Total positions of person(s) subject to the notification obligation

% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of issuervii

Resulting situation on the date on which threshold was crossed or reached

5.18

0

5.18

6,048,880

Position of previous notification (if

applicable)

10.2

0

10.2

 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii

A: Voting rights attached to shares

Class/type ofshares

ISIN code (if possible)

Number of voting rightsix

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

ORD GBP0.10

6,048,880

5.18%

SUBTOTAL 8. A

6,048,880

5.18%

 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial instrument

Expirationdatex

Exercise/Conversion Periodxi

Number of voting rights that may be acquired if the instrument is

exercised/converted.

% of voting rights

SUBTOTAL 8. B 1

 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of financial instrument

Expirationdatex

Exercise/Conversion Period xi

Physical or cash

settlementxii

Number of voting rights

% of voting rights

SUBTOTAL 8.B.2

 

 

 

 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii

Full chain of controlled undertakings through which the voting rights and/or thefinancial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv (please add additional rows as necessary)

x

Namexv

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial instruments if it equals or is higher than the notifiable threshold

Total of both if it equals or is higher than the notifiable threshold

STEWART NEWTON

 N/A

N/A

SUSSEX RESEARCH LTD

N/A

N/A

10. In case of proxy voting, please identify:

Name of the proxy holder

The number and % of voting rights held

The date until which the voting rights will be held

11. Additional informationxvi

 

Place of completion

London

Date of completion

10th October 2017

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLEANEAFSKXFEF
Date   Source Headline
1st Feb 20199:12 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
31st Jan 201910:06 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
29th Jan 201910:19 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
25th Jan 20198:55 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
22nd Jan 20199:10 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
14th Jan 20199:44 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
11th Jan 20199:39 amRNSForm 8.5 (EPT/RI) - Realm Therapeutics Plc
8th Jan 201910:41 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
4th Jan 20199:46 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
3rd Jan 20199:53 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
2nd Jan 20199:26 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
27th Dec 201810:47 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
24th Dec 201810:18 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
21st Dec 201810:26 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
20th Dec 201810:26 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
20th Dec 20188:54 amRNSForm 8.3 - Realm Therapeutics plc
19th Dec 201810:27 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
13th Dec 20189:35 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
10th Dec 20181:20 pmRNSForm 8.3 - Realm Therapeutics plc
10th Dec 201810:32 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
6th Dec 201810:46 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
5th Dec 20189:56 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
4th Dec 201812:20 pmRNSForm 8.5 (EPT/RI) Realm therapeutics
3rd Dec 201811:20 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
30th Nov 20184:08 pmRNSHolding(s) in Company
30th Nov 20181:18 pmRNSForm 8.3 - Realm Therapeutics plc
30th Nov 201811:39 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
29th Nov 201811:58 amRNSHolding(s) in Company
29th Nov 201811:13 amRNSForm 8.3 - Realm Therapeutics plc
29th Nov 20189:55 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
29th Nov 20187:00 amRNSUpdate on Strategic Review
28th Nov 201810:19 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
28th Nov 20189:53 amRNSForm 8.3 - Realm Therapeutics plc
27th Nov 20186:28 pmRNSForm 8.3 - Realm Therapeutics plc
26th Nov 201811:22 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
26th Nov 20188:41 amRNSForm 8.3 - Realm Therapeutics plc
12th Nov 20188:32 amRNSForm 8.5 (EPT/RI) Realm therapeutics
7th Nov 20185:14 pmRNSHolding(s) in Company
7th Nov 201810:37 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
7th Nov 20189:03 amRNSForm 8.3 - Realm Therapeutics plc
6th Nov 201810:36 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
2nd Nov 201811:31 amRNSForm 8.3 - Realm Therapeutics plc
31st Oct 20189:04 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
25th Oct 20189:34 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
19th Oct 201810:23 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
17th Oct 201810:37 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
16th Oct 20189:31 amRNSForm 8.5 (EPT/RI) Realm therapeutics
15th Oct 20189:34 amRNSForm 8.3 - Realm Therapeutics plc
15th Oct 20189:24 amRNSForm 8.5 (EPT/RI) Realm Therapeutics
12th Oct 20188:58 amRNSForm 8.5 (EPT/RI) Realm Therapeutics

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.